Hemangioma Clinical Trial
Official title:
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial
to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.
The clinically commonly used dose of sirolimus for Kaposiform Hemangioendothelioma is 0.8 mg/m2 administered twice daily, and the blood concentration can be maintained at 10-15 ng/ml according to the pharmacokinetic formula.Related research reports that maintaining low blood concentration of sirolimus is effective in the treatment of certain vascular malformations and hemangioma, and complications are less. In the clinical practice, we found that the blood concentration was maintained at 7-10 ng/ml, and the patients still achieved good results and the chance of infections decreased. Therefore, this clinical trial was designed.In this trial, two different dosing regimens with corresponding blood concentration were designed to compare the safety and efficacy.In the high concentration group, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL(excluding 10 ng/ml), and it is still used at 0.8 mg/m2 administered twice daily.The low concentration group is 7-10 ng/ml (including 10 ng/ml), and the initial use of sirolimus is 0.7mg/m2 administered twice daily.The dose was adjusted according to the formula after two weeks.The follow-up and evaluation were performed according to a strictly established follow-up schedule after taking the drug. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01685398 -
Topical Timolol for Superficial Infantile Hemangioma
|
Phase 3 | |
| Withdrawn |
NCT00974129 -
A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas
|
N/A | |
| Completed |
NCT00374335 -
Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
|
N/A | |
| Recruiting |
NCT03331744 -
Clinical Characteristics of Infantile Hemangioma
|
||
| Completed |
NCT02342275 -
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
|
Phase 3 | |
| Completed |
NCT00433940 -
Immune Suppression Of Infants Treated With Steroids
|
N/A | |
| Completed |
NCT04065217 -
The Effectiveness of Diode Laser 980-nm in Iraqi Face Hemangioma: a Randomized Within Patients Trial
|
N/A | |
| Terminated |
NCT01743885 -
Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma
|
Phase 3 | |
| Terminated |
NCT00555464 -
Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas
|
Phase 2 | |
| Completed |
NCT00394888 -
Hemangioma Associated With High Rates of Morbidity
|
N/A | |
| Completed |
NCT05327309 -
Role of Propranolol as Compared to Bleomycin in Management of Hemangioma
|
N/A | |
| Completed |
NCT02145884 -
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
|
Phase 2 | |
| Completed |
NCT02731287 -
Topical Timolol for Infantile Hemangioma in Early Proliferative Phase
|
Phase 2 | |
| Recruiting |
NCT01147601 -
Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas
|
Phase 0 | |
| Completed |
NCT01908972 -
The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
|
Phase 4 | |
| Completed |
NCT00540566 -
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
|
||
| Completed |
NCT00001417 -
Direct Injection of Alcohol for the Treatment of Spinal Tumors
|
N/A | |
| Completed |
NCT00004436 -
Randomized Study of Hormonal Regulation of Infantile Hemangioma
|
N/A | |
| Recruiting |
NCT02496013 -
Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB
|
Phase 1 | |
| Completed |
NCT01072045 -
Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma
|
Phase 2 |